Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma

---
Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma
Vote:
0 0
Previous Ascenda and Galileo Financial Technologies Collaborate to Elevate Card Loyalty Programs
Next SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

Related News

U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

HanX Biopharmaceuticals announces HX009 IND approval from FDA

IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

menu
menu